<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
<url>
  <loc>https://butterflymarketinsider.com/regulated-utility-rate-base-allowed-roe-ai-power-demand-deep-dive/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>en</news:language>
    </news:publication>
    <news:publication_date>2026-09-09T07:40:23+00:00</news:publication_date>
    <news:title>Same Wire, Half the Return: Why a Regulator, Not the AI Boom, Decides What a Utility Earns</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/fr/novartis-avidity-del-desiran-harbor-strategie-acquisitions-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>fr</news:language>
    </news:publication>
    <news:publication_date>2026-09-08T11:59:15+00:00</news:publication_date>
    <news:title>12 milliards payés, 29,6 perdus : chez Novartis, ce n’est pas un médicament qui est tombé, c’est une stratégie</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/it/novartis-avidity-del-desiran-harbor-strategia-acquisizioni-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>it</news:language>
    </news:publication>
    <news:publication_date>2026-09-08T11:59:14+00:00</news:publication_date>
    <news:title>12 miliardi pagati, 29,6 persi: in Novartis non è caduto un farmaco, è caduta una strategia</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/es/novartis-avidity-del-desiran-harbor-estrategia-adquisiciones-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>es</news:language>
    </news:publication>
    <news:publication_date>2026-09-08T11:59:14+00:00</news:publication_date>
    <news:title>12.000 millones pagados, 29.600 perdidos: en Novartis no cayó un medicamento, cayó una estrategia</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/en/novartis-avidity-del-desiran-harbor-acquisition-strategy-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>en</news:language>
    </news:publication>
    <news:publication_date>2026-09-08T11:59:13+00:00</news:publication_date>
    <news:title>12 Billion Paid, 29.6 Billion Lost: What Fell at Novartis Was Not a Drug but a Strategy</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/de/novartis-avidity-del-desiran-harbor-uebernahmestrategie-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>de</news:language>
    </news:publication>
    <news:publication_date>2026-09-08T11:59:12+00:00</news:publication_date>
    <news:title>12 Milliarden bezahlt, 24 Milliarden verloren: Bei Novartis fiel an einem Tag nicht ein Medikament, sondern eine Strategie</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/fr/kospi-5-3-fois-benefices-cycle-memoire-coree-valorisation-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>fr</news:language>
    </news:publication>
    <news:publication_date>2026-09-07T12:01:29+00:00</news:publication_date>
    <news:title>66 pour cent plus cher, 64 pour cent moins cher : pourquoi la meilleure Bourse du monde ne vaut que 5,3 fois les bénéfices</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/it/kospi-5-3-volte-utili-ciclo-memorie-corea-valutazione-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>it</news:language>
    </news:publication>
    <news:publication_date>2026-09-07T12:01:28+00:00</news:publication_date>
    <news:title>66 per cento più caro, 64 per cento più economico: perché la migliore borsa del mondo vale solo 5,3 volte gli utili</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/es/kospi-5-3-veces-beneficios-ciclo-memoria-corea-valoracion-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>es</news:language>
    </news:publication>
    <news:publication_date>2026-09-07T12:01:27+00:00</news:publication_date>
    <news:title>66 por ciento más caro, 64 por ciento más barato: por qué la mejor bolsa del mundo cotiza a solo 5,3 veces</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/en/kospi-5-3-times-earnings-memory-cycle-korea-valuation-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>en</news:language>
    </news:publication>
    <news:publication_date>2026-09-07T12:01:26+00:00</news:publication_date>
    <news:title>66 Percent Dearer, 64 Percent Cheaper: Why the World’s Best Stock Market Costs Just 5.3 Times Earnings</news:title>
  </news:news>
</url>
<url>
  <loc>https://butterflymarketinsider.com/de/kospi-5-3-faches-kgv-speicherzyklus-korea-bewertung-2026/</loc>
  <news:news>
    <news:publication>
      <news:name>BMInsider</news:name>
      <news:language>de</news:language>
    </news:publication>
    <news:publication_date>2026-09-07T12:01:25+00:00</news:publication_date>
    <news:title>66 Prozent teurer, 64 Prozent billiger: Warum der beste Aktienmarkt der Welt nur das 5,3-Fache kostet</news:title>
  </news:news>
</url>
</urlset>
